Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Recruiting · NCT04332367 · Interventional (participants receive a specific treatment) · Lead sponsor: Abramson Cancer Center at Penn Medicine
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.
- PS 0-1
Exclusion criteria
- Presence of a driver mutation that is susceptible to targeted therapy
- Other active invasive malignancy requiring ongoing therapy
- Grade 2 or higher sensory neuropathy
- Evidence of untreated brain metastases
- History of bleeding diatheses or recent, antecedent hemoptysis (\> 1/2 teaspoon in prior 2 months)
Where it is running
1 location listed across 1 US state.
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia, Pennsylvania, United States